Pharma Intelligence | 2018 R&D Review: 5 Key Takeaways

I haven’t read the full report only the article and it is interesting to read as a patient, patient group leader and as a non-pharma reader,.

I do think it important to share these reports so that people can read them no matter which area of the med care industry they are based in.

FibroFlutters like to encourage people to look out of the window once in a while to see what is going on around them within other areas of the med care industry.  This is because each area does appear to have a knock on effect on all the others, a bit like dominoe rallies.  Of course this is a natural side effect of making changes, they are bound to effect others somewhere else along the supply chain.

Want to be effective, then take a peek, look around you and see what’s happening elsewhere!

Pharma Intelligence | 2018 R&D Review: 5 Key Takeaways

#Pharmaceutical R&D pipeline size for 2018 (January) stands at 15,267, an all-time high which makes this the seventh consecutive year of expansion.

Link to the article >>>

Twitter tags:


Pharma Intelligence on Twitter  >>>

Trusted partner of the top 50 global pharmaceutical companies and the top 10 CRO’s – providing timely intelligence and insight to make authoritative decisions.

Visit the Pharma Intelligence website for pharma articles, resource hub, events, webinars and much more, and you can also opt-in for e-news  >>>